Cyclooxygenase-2 is an independent prognostic factor in gastric carcinoma patients receiving adjuvant chemotherapy and is not associated with EBV infection

Clinical Cancer Research

Volumn 15, Issue 1, 2009, Pages 291-298

  Park, Eun Soo ^a   Do, In Gu ^a   Park, Cheol Keun ^a   Kang, Won Ki ^b   Noh, Jae Hyung ^c   Sohn, Tae Sung ^c   Kim, Sung ^c   Kim, Min Ji ^d   Kim, Kyoung Mee ^a,c  

^a Department of Pathology ^*  (South Korea)

^b Division of Hematology/Oncology   (United States)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Samsung Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; PROTEIN MLH1; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; EPSTEIN BARR VIRUS; FEMALE; GASTRECTOMY; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CARCINOMA; TISSUE MICROARRAY; TUMOR LOCALIZATION; VIRUS INFECTION;

CHEMOTHERAPY, ADJUVANT; CYCLOOXYGENASE 2; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 58849086027     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0848     Document Type: Article

References (33)

1. Wu MS, Shun CT, Wu CC, et al Epstein-Barr virus- associated gastric carcinomas: relation to H. pylori infection and genetic alterations Gastroenterology 2000;118:1031 -8.
2. Kang GH, Lee S. Kim WH, et al. Epstein-Barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-7positive gastric carcinoma. Am J Pathol 2002; 160:787-94.
3. Herschman HR. Prostaglandin synthase 2 Biochim Biophys Acta 1996;1299:125-40.
4. El-Bayoumy K, latropoulos M, Amin S, Hoffmann D, Wynder EL. Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-4-(3-pyridyl)-1 - butanone: the impact of a high-fat diet. Cancer Res 1999;59:1400-3.
5. Leung WK, To KF, Go MY, et al. Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma. Int J Oncol 2003;23:1317-22.
6. Tatsuguchi A, Matsui K, Shinji Y, et al. Cyclooxyge- nase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue. Hum Pathol 2004; 35:488-95.
7. Murata H, Kawano S,Tsuji S, et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999;94:451 -5.
8. Peek RM, Jr., Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002;2:28-37.
9. Konturek PC, Kania J, Burnat G, Hahn EG, Konturek SJ. Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract. J Physiol Pharmacol 2005;56 Suppl 5:57-73.
10. Liu F, Pan K, Zhang X, et al. Genetic variants in cyclooxygenase-2: expression and risk of gastric cancer and its precursors in a Chinese population. Gastroenterology 2006;130:1975-84.
11. Saukkonen K, Nieminen O, van Rees B, et al. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res 2001;7:1923-31.
12. Yamagata R, Shimoyama T, Fukuda S, Yoshimura T, Tanaka M, Munakata A. Cyclooxygenase-2 expression is increased in early intestinal-type gastric cancer and gastric mucosa with intestinal metaplasia. Eur J Gastroenterol Hepatol 2002;14:359-63.
13. van Rees BP, Saukkonen K, Ristimaki A, et al. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol 2002;196:171 -9.
14. Joo YE, Oh WT, Rew JS, Park CS, Choi SK, Kim SJ. Cyclooxygenase-2 expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis. Digestion 2002;66:222-9.
15. Mrena J, Wiksten JP, Thiel A, et al. Cyclooxyge- nase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor Hu R. Clin Cancer Res 2005; 11:7362-8.
16. de Maat MF, van de Velde CJ, Umetani N, et al. Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol 2007;25: 4887-94.
17. Minoura-Etoh J, Gotoh K, Sato R, et al. Helicobacter pylori-associated oxidant monochloramine induces reactivation of Epstein-Barr virus (EBV) in gastric epithelial cells latently infected with EBV. J Med Microbiol 2006;55:905-11.
18. Lee J, Park CK, Park JO, et al. Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. Clin Cancer Res 2008;14:82-8.
19. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345:725-30.
20. Berger AC, Sigurdson ER, LeVoyerT, et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005;23:8706-12.
21. + NK lymphomas: clinicopathological features and prognosis. Br J Haematol 1997;97:821 -9.
22. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31 -49.
23. Lim HY, Joo HJ, Choi JH, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000;6:519-25.
24. Cho HJ, Kim JY, Yoo J, Lee SS. Gastric carcinoma with lymphoid stroma: incidence of EBV and Helicobacter pylori infection. Appl Immunohistochem Mol Morphol 2003;11:149-52.
25. van Beek J, zur Hausen A, Klein Kranenbarg E, et al. EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol 2004;22:664-70.
26. Sudo M, Chong JM, Sakuma K, et al. Promoter hypermethylation of E-cadherin and its abnormal expression in Epstein-Barr virus-associated gastric carcinoma. Int J Cancer 2004;109:194-9.
27. Kijima Y, Ishigami S, Hokita S, et al. The comparison of the prognosis between Epstein-Barr virus (EBV)-positive gastric carcinomas and EBV-negative ones. Cancer Lett 2003;200:33-40.
28. Lim S, Lee HS, Kim HS, Kim Yl, Kim WH. Alteration of E-cadherin-mediated adhesion protein is common, but microsatellite instability is uncommon in young age gastric cancers. Histopathology 2003;42: 128-36.
29. Koriyama C, Akiba S, Itoh T, et al. Prognostic significance of Epstein-Barr virus involvement in gastric carcinoma in Japan. Int J Mol Med 2002;10: 635-9.
30. Saito H, Fukumoto,Y Osaki T, et al. Prognostic significance of level and number of lymph node metastases in patients with gastric cancer. Ann Surg Oncol 2007;14:1688-93.
31. Slidell MB. Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 2008;15:165- 74.
32. De Ridder M, Vinh-Hung V, Van Nieuwenhove Y, Hoorens A, Sermeus A, Storme G. Prognostic value of the lymph node ratio in node positive colon cancer Gut 2006;55:1681.
33. Marchet A, Mocellin S, Ambrosi A, et al The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy results from an Italian multicentric study in 1853 patients. Ann Surg 2007;245:543 52.